Ads
related to: pembrolizumab clinical trials
Search results
Earnings call: Compugen outlines progress and plans in Q1 2024 earnings By Investing.com
Investing.com· 18 hours agoThe company highlighted its successful transition of AI-predicted drug targets to clinical trials...
Earnings call: AIM ImmunoTech highlights Q1 2024 progress on cancer trials
Investing.com· 5 days agoAIM ImmunoTech (NYSE: AIM ) Inc. (NYSE American: AIM) provided an optimistic update during its first...
Precigen Reports First Quarter 2024 Financial Results and Business Updates
WRBL Columbus· 7 days ago– Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking oral presentation ...
AIM ImmunoTech Inc (AIM) (Q1 2024) Earnings Call Transcript High
Guru Focus· 5 days agoFor the complete transcript of the earnings call, please refer to the full earnings call transcript. AIM ImmunoTech Inc reported positive safety and tolerability results from the Duripanc study ...
Earnings call: BioAtla reports promising data in cancer drug trials By Investing.com
Investing.com· 6 days agoBioAtla, a biotechnology company, has announced its first-quarter financial results and provided a...
Does AI Really Make Moderna Stock (NASDAQ:MRNA) a Buy?
TipRanks via Yahoo Finance· 4 days agoHowever, the company is once again on the move — in a good way. The stock is up 68% over the past...
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
InvestorPlace· 5 days agoPenny stocks to buy understandably offer many enticing attributes, not least of which is the...
Immutep shares gain as CapitalOne sets $10 target on cancer drug potential By Investing.com
Investing.com· 4 days agoOn Friday, Immutep Limited (NASDAQ:IMMP) received a positive assessment from CapitalOne, as the firm...
BioAtla Inc (BCAB) (Q1 2024) Earnings Call Transcript Highlights: Strategic Adjustments and ...
GuruFocus.com via Yahoo Finance· 6 days agoA: (Richard Waldron, CFO) The monotherapy trial included a broad range of melanomas and relapsed refractory carcinomas. We have treated three patients at the one gram dosing ...
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results
Morningstar· 7 days agoKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial ...
Ads
related to: pembrolizumab clinical trials
